

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Peijia Medical Limited**

### **沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

## **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN THE COMPOSITION OF BOARD COMMITTEES**

### **APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR**

Reference is made to the announcement of Peijia Medical Limited (the “**Company**”) dated June 21, 2021.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that Mr. Wei Huacheng (“**Mr. Wei**”) has been appointed as an independent non-executive Director, a member of the audit committee, the remuneration committee and the nomination committee of the Company, with effect from September 20, 2021.

Biographical details of Mr. Wei are set out below:

Mr. Wei, aged 61, graduated from Central South Institute of Mining and Metallurgy with a bachelor’s degree in metallurgical machinery in 1982. Mr. Wei obtained his master’s degree in business administration from Tsinghua University in 1999 and his doctoral degree in management from Huazhong University of Science and Technology in 2004. Mr. Wei has considerable experience in medical industry as he served as the Party Secretary and the chairman of Beijing Pharmaceutical Group Company Limited, the Party Secretary and the chairman of Beijing Double-Crane Pharmaceuticals Co., Ltd. (now known as CR Double-Crane Pharmaceuticals Co., Ltd., a company listed on the Shanghai Stock Exchange (stock code: SHA 600062)), the chairman of the supervisory committee of Beijing Wandong Medical Technology Co., Ltd. (a company listed on the Shanghai Stock Exchange (stock code: SHA 600055)), and the deputy general manager of China Resources Pharmaceutical Group Limited. He has subsequently been a standing committee member of the Party Committee of Beijing Automotive Group Co., Ltd. since February 2013, and he served as the vice chairman of Beijing Automotive Group Co., Ltd. from February 2013 to April 2021. From June 2006 to June 2012, he served as the chairman of the supervisory committee of Beijing Wandong Medical Technology Co., Ltd. (a company listed on the Shanghai Stock Exchange (stock code: SHA 600055)). He has been an adjunct professor of Huazhong University of Science and Technology (華中科技大學) since 2005 and a visiting professor of Renmin University of China (中國人民大學) since 2008.

The Company has issued a letter of appointment to Mr. Wei, who shall serve as an independent non-executive Director of the Company commencing on September 20, 2021 and continuing until the next annual general meeting of the Company, upon which Mr. Wei shall stand for re-election by the shareholders of the Company as an independent non-executive Director. Subject to approval at the next annual general meeting of the Company, Mr. Wei shall serve as an independent non-executive Director for a term of three years commencing from the date of the next annual general meeting of the Company, subject to retirement by rotation and re-election at subsequent annual general meetings of the Company in accordance with the memorandum and articles of association of the Company. Under the letter of appointment, Mr. Wei will be entitled to an annual remuneration of HKD350,000 in relation to his appointment and service as an independent non-executive Director.

Save as disclosed above, Mr. Wei confirmed that, he has not held any directorship, and/or any other major appointment and professional qualification in other companies listed on The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and/or overseas in the last three years. He has no relationships with any Directors, senior management or substantial shareholders or controlling shareholders of the Company, has no other major positions in the Company and its subsidiaries, and does not have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporation which are required to be disclosed pursuant to Part XV of the Securities and Future Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Mr. Wei as an independent non-executive Director that need to be brought to the attention of the shareholders of the Company and the Hong Kong Stock Exchange. There is no other information which is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange.

The Board would like to extend its welcome to Mr. Wei to join the Board.

## **CHANGE IN THE COMPOSITION OF REMUNERATION COMMITTEE**

Mr. Robert Ralph Parks has been appointed as the chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) with effect from September 20, 2021. After that, the members of the Remuneration Committee are Dr. Zhiyun Yu, Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks (Chairman) and Mr. Huacheng Wei.

By order of the Board  
**Peijia Medical Limited**  
沛嘉醫療有限公司  
**Dr. Yi Zhang**  
*Chairman and executive Director*

Hong Kong, September 20, 2021

*As of the date of this announcement, the executive Directors are Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye, the non-executive Directors are Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, and Mr. Jun Yang, and the independent non-executive Directors are Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip and Mr. Huacheng Wei.*